Evidence map›Paper›PMID 42734657›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026

Autoimmune processes and production of catalytically active antibodies-abzymes in prone to amyotrophic lateral sclerosis FUS(1-359) mice.

Andrey E Urusov, Marina A Gorobets, Kseniya S Aulova, Anna M Timofeeva, Ludmila B Toporkova, Irina A Orlovskaya, Aleksey A Ustyugov, Georgy A Nevinsky

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrey E UrusovInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia.
Marina A GorobetsInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia.
Kseniya S AulovaInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia.
Anna M TimofeevaInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia.
Ludmila B ToporkovaInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia.
Irina A OrlovskayaInstitute of Clinical Immunology, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Russia.
Aleksey A UstyugovInstitute of Physiologically Active Compounds at Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences, Chernogolovka, Russian Federation.
Georgy A NevinskyInstitute of Chemical Biology and Fundamental Medicine of the Siberian Division of RAS, Lavrentiev Ave. 8, Novosibirsk, 630090, Russia. nevinsky@niboch.nsc.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIt was shown previously that the development of not only many autoimmune (AIDs) but also neurological and neurodegenerative diseases (NDDs) including multiple sclerosis, tick-borne encephalitis, and schizophrenia in humans and experimental mice models occurs due to a specific destruction of the immune system. This error in the immune system leads to the formation of B lymphocytes producing adverse antibodies-abzymes possessing different catalytic activities.

methodsOne of the earliest and statistically reliable index of developments of autoimmune reactions is the appearance in the blood abzymes that are absent in conditionally healthy donors. We investigated the in time changes catalytic activities of Abs-abzymes using standard methods of enzymology.

resultsIt was shown for the first time that, as in the case of various AIDs and NDDs, the early stages of ALS development in FUS(1-359) mice are also associated with the production of catalytic antibodies. CD-1 mice utilized for obtaining FUS(1-359) mice were also used. IgG samples were isolated from the blood of transgenic FUS(1-359) mice and their non-transgenic siblings (CD1) at different times. The first signs of ALS-like symptoms develop at the age of ≥ 2 months of life in FUS(1-359) mice, which was taken as zero time point, and then by ≥ 80 days of age, deep pathology was observed. It was shown for the first time that antibodies from the blood of FUS(1-359) mice exhibit DNase, amylase, phosphatase, and catalase catalytic activities beginning from 2 months of age. However, unlike non-transgenic siblings, the relative activity of mice IgGs was higher in FUS(1-359) mice. All activities of FUS(1-359) mice IgGs began to increase significantly starting from 20 to 30 days after beginning of experiments and achieved maximum upon reaching deep pathology.

conclusionsThe data obtained indicate that in the early stages of ALS development in FUS(1-359) mice containing genes associated with this pathology in humans, there is a disruption of the immune system and production of abzymes that destroy components of blood, cells and tissues. One cannot exclude that such autoimmune reactions are important for development of ALS in FUS(1-359) mice.

Indexed as

Amyotrophic Lateral SclerosisAntibodies, CatalyticRNA-Binding Protein FUSAnimalsAutoimmunityDisease Models, AnimalFemaleImmunoglobulin GMiceMice, TransgenicAntibodies, CatalyticImmunoglobulin GRNA-Binding Protein FUSAmylaseCatalase activities of antibodiesCatalytic IgGsCD1 miceFUS(1-359) mouse model of Amyotrophic lateral sclerosisHydrolysis of DNAPhosphatase

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.